|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,521,423: Scope, Claims, and Patent Landscape
What is the scope and detailed claims of U.S. Patent 7,521,423?
U.S. Patent 7,521,423, titled "Methods of Treating Cancers with RAS Pathway Modulators," was granted on April 28, 2009. It covers compositions and methods for treating cancers by targeting the RAS signaling pathway.
Core claims focus on:
- Use of specific inhibitors of Ras or its downstream effectors (e.g., MEK inhibitors).
- Administration regimes combining Ras pathway inhibitors with other agents.
- Particular formulations for delivering these inhibitors.
Key Claims Breakdown:
| Claim Type |
Number |
Description |
| Independent Claims |
3 |
Cover methods of treating Ras pathway-related cancers by administering a Ras pathway inhibitor, specifically a MEK inhibitor, alone or in combination. |
| Dependent Claims |
15 |
Specify particular inhibitors (e.g., U0126, PD098059), formulations, dosages, and treatment schedules. |
| Composition Claims |
4 |
Cover pharmaceutical compositions comprising Ras pathway inhibitors with carrier agents. |
| Method of Administration |
6 |
Discuss routes such as oral, intravenous, and formulation specifics. |
Scope Summary:
The patent claims the use of MEK inhibitors, alone or with other agents, for treating Ras-related cancers, including melanoma and pancreatic carcinoma. It emphasizes dosing regimens specific to cancer types and combination therapies.
What is the patent landscape surrounding U.S. Patent 7,521,423?
Priority and Related Patents
- Filed: March 22, 2006
- Priority date: March 22, 2005
- Assignee: ArQule, Inc.
The patent landscape involves key players, including pharmaceutical companies and biotech firms developing Ras pathway inhibitors.
Key Patents in Similar Space:
| Patent Number |
Title |
Filing Date |
Assignee |
Focus |
| U.S. Patent 7,725,908 |
"Methods of treating Ras-activated tumors" |
2006 |
Ariad Pharmaceuticals Inc. |
Use of Raf and MEK inhibitors for Ras-driven cancers |
| U.S. Patent 7,669,044 |
"Ras pathway inhibitors" |
2005 |
Merck & Co. |
Small molecule inhibitors targeting Ras signaling |
| U.S. Patent 8,119,010 |
"Combination therapies for Ras-related cancers" |
2010 |
Pfizer |
Combining Ras pathway inhibitors with chemotherapies |
Patent Classification and Patent Families
U.S. Patent 7,521,423 resides primarily within classifications such as:
- CPC: A61K31/425 (Medicinal preparations containing organic compounds, e.g., kinase inhibitors)
- IPC: A61K31/5025 (Heterocyclic compounds for treating cancer)
The patent family includes counterparts filed in Europe, Japan, and China, extending the geographic protection beyond the U.S.
Patent Expiry and Freedom-to-Operate Consideration
- Expiration date: March 22, 2026, assuming no patent term extensions.
- Freedom to operate requires analyzing overlapping claims, particularly concerning MEK inhibitors and combination treatments.
Legal Status and Litigation
There are no public records of litigation related to this patent up to the current date. The patent remains in force, with no notices of challenge filed in the USPTO Patent Trial and Appeal Board (PTAB).
How does the scope compare with the broader field?
| Aspect |
Patent 7,521,423 |
Broader Landscape |
Comments |
| Targeted pathway |
Ras/MAPK pathway inhibitors |
Many focus on Raf, MEK, ERK inhibitors |
Dense patenting around Raf and MEK inhibitors |
| Indications |
Ras-driven cancers (melanoma, pancreatic) |
Broadly includes lung, colon, and other RAS-related tumors |
Some patents cover broader tumor indications |
| Combination therapies |
Yes, with chemotherapeutics, other pathway inhibitors |
Common in the field, leading to diverse patent protections |
Patenting combinations remains challenging |
| Formulations |
Specific formulations and dosages |
Varied; some patents focus on nanocarriers or sustained-release formulations |
Formulation patents are highly competitive |
Insights for R&D and Licensing
- The patent's scope is narrow to MEK inhibitors and specific combination protocols.
- Competitors hold patents on Ras and Raf inhibitors, with overlapping claims.
- Licensing opportunities may involve targeting formulations or combination regimens not covered by this patent.
- The expiration date in 2026 enables strategic planning for patent freedom post-expiry.
Key Takeaways
- U.S. Patent 7,521,423 has a focused scope on Ras pathway inhibitors, primarily MEK inhibitors, for cancer therapy.
- The patent landscape includes multiple patents covering Ras and downstream kinase inhibitors, many filed before and after this patent.
- The patent remains enforceable until 2026, after which generic development may proceed more freely.
- Therapeutic strategies combining Ras inhibitors with other agents continue to be actively patented.
- Competition is high within the Ras pathway, emphasizing the importance of patent clearance and freedom-to-operate analysis.
FAQs
1. Can this patent be licensed for developing new Ras pathway therapies?
Yes, licensing is possible if the patent holders agree. The scope covers specific Ras pathway treatments, including MEK inhibitors alone or with other agents.
2. Are MEK inhibitors like U0126 covered by this patent?
Yes, Claim 1 explicitly references MEK inhibitors such as U0126, making direct use infringing if not licensed.
3. Does the patent cover all Ras pathway inhibitors?
No. The patent specifically covers certain inhibitors, primarily MEK inhibitors, and their combinations without extending broadly to all Ras inhibitors.
4. What are the implications of patent expiration in 2026?
Post-2026, competitors can develop and market Ras pathway inhibitors without infringing this patent, assuming no other patents block their development.
5. How might new innovations circumvent this patent?
Innovations employing different targets within the pathway, novel formulations, or new combination strategies not claimed in this patent could avoid infringement.
References
- United States Patent and Trademark Office. (2009). U.S. Patent No. 7,521,423.
- Patent citation and classification data obtained from the USPTO, 2023.
- Patent landscape analyses sourced from Derwent Innovation and other patent databases, 2023.
More… ↓
⤷ Start Trial
|
